Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):
-Earnings: -$76.79 million in Q3 vs. -$43.99 million in the same period last year.
-EPS: -$0.91 in Q3 vs. -$0.58 in the same period last year.
-Analysts projected -$0.91 per share
-Revenue: $6.32 million in Q3 vs. $10.97 million in the same period last year.
For comments and feedback contact: editorial@rttnews.com